1. Home
  2. FNLC vs LUNG Comparison

FNLC vs LUNG Comparison

Compare FNLC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$26.33

Market Cap

288.7M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.29

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
LUNG
Founded
1864
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.7M
63.6M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
FNLC
LUNG
Price
$26.33
$2.29
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
21.0K
874.9K
Earning Date
01-21-2026
02-18-2026
Dividend Yield
5.60%
N/A
EPS Growth
18.07
N/A
EPS
2.81
N/A
Revenue
$88,119,000.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
$9.40
N/A
Revenue Growth
12.70
15.59
52 Week Low
$22.11
$1.31
52 Week High
$28.60
$9.37

Technical Indicators

Market Signals
Indicator
FNLC
LUNG
Relative Strength Index (RSI) 44.37 54.91
Support Level $26.20 $2.17
Resistance Level $26.73 $2.35
Average True Range (ATR) 0.46 0.15
MACD -0.21 -0.04
Stochastic Oscillator 6.97 27.00

Price Performance

Historical Comparison
FNLC
LUNG

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: